Our analysis unveiled that AML cells carrying MLL fusions, such as MOLM-13 (MLL-AF9), THP-1 (MLL-AF9), MV4-11 (MLL-AF4) and NOMO1 (MLL-AF9), are relatively more sensitive to the inhibitors compared to AML cells without MLL fusions (Supplementary Fig. 3r, s). The gene discussed is MLLT3; the disease is acute myeloid leukemia.